Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBCombination therapies in CLL are generating excitement with ongoing trials that could expand standard practice for the future. Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
High-Dose Radiation Plus Long-Term ADT Improves Survival in …
WEBJan 25, 2024 — Utilizing a higher dose of radiation therapy in combination with the long-term use of androgen deprivation therapy (ADT) improved survival outcomes after 10 years of follow-up in patients with high-risk prostate cancer, according to long-term results from the GETUG-AFU 18 trial (NCT00967863) presented at the 2024 ASCO Genitourinary Cancers ...
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
WEBDec 8, 2023 — After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
Next Generation Androgen Receptor Inhibitors - Targeted Oncology
WEBNov 10, 2021 — There are currently 4 approved androgen receptor pathway inhibitors in the United States: 3 anti-androgens—apalutamide, enzalutamide, and darolutamide—and an androgen receptor pathway inhibitor, abiraterone acetate. The efficacy of these agents, while rarely studied head-to-head, appears remarkably …
Unpacking the EMERALD-1 Treatment Approach for HCC
WEBJan 19, 2024 — Riccardo Lencioni, MD, professor in the department of radiology at the University of Pisa School of Medicine in Pisa, Italy, discusses how the new protocol from the phase 3 EMERALD-1 trial (NCT03778957) of durvalumab (Imfinzi), transarterial chemoembolization (TACE), and bevacizumab (Avastin) may be implemented in the community oncology setting for the treatment of hepatocellular carcinoma (HCC).
Balancing Treatment Efficacy and Adverse Events in Multiple …
WEBJul 17, 2024 — Balancing Treatment Efficacy and Adverse Events in Multiple Myeloma. During a Case-Based Roundtable® event, Andrew Yee, MD, discussed the use of carfilzomib-based regimens compared with other options for patients with multiple myeloma, including those refractory to lenalidomide in the first article of a 2-part series.
Risk Stratification Tools for MDS: IPSS, IPSS-R, IPSS-M - Targeted …
WEBJan 10, 2024 — Some patients classified as low risk by IPSS-R are upstaged to higher-risk disease by IPSS-M. With 6 risk strata, IPSS-M provides more precise classification. However, clinical trials and treatment selections still rely on traditional IPSS/IPSS-R. With time, IPSS-M will be incorporated into research and practice to guide management.
Melanoma - Targeted Oncology
WEBMarch 18th 2024. In patients with advanced melanoma, lifileucel showed durable efficacy and a 4-year overall survival rate of 21.9%, according to long-term findings from the phase 2 C-144-01 trial. Read More. TILT-123/TIL Combo Appears Safe and Feasible in …
Recent Approvals Signal a Bright Future for Myelodysplastic …
WEBDec 22, 2023 — Ivosidenib . In October 2023, ivosidenib (Tibsovo) was cleared by the FDA for the treatment of IDH1-mutated relapsed or refractory MDS, based on findings from the AG120-C-001 trial (NCT02074839).4 In the study, 18 adult patients with relapsed or refractory MDS with an IDH1 mutation received oral ivosidenib daily on a 28-day cycle. All responses in the trial were complete responses (CRs), and ...
Chronic Lymphocytic Leukemia - Targeted Oncology
WEBSeptember 20th 2024. The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited therapy may be feasible in certain cases, particularly when combined with other targeted agents. Various Combinations With Venetoclax Show Positive Signs in CLL. By Morgan Bayer.